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Background: Antimalarial antibody measurements are useful because they reflect
historical and recent exposure to malaria. As such, they may provide additional
information to assess ongoing transmission in low endemic or pre-elimination settings
where cases are rare. In addition, the absence of antibody responses in certain
individuals can indicate the cessation of transmission. Commercial malaria enzyme-linked
immunosorbent assays (ELISA) detect antimalarial antibodies and are commonly used to
screen blood donations for possible malaria infection. However, there is no standardized
test to detect antimalarial antibodies for epidemiological use. Here we compared five
commercially available ELISA kits (Trinity Biotech, newbio, DiaPro, Cellabs, and NovaTec)
in search of a standardized tool for supporting claims of absence of malaria transmission.
For comparison, a research-based (RB) ELISA protocol was performed alongside the
commercial kits.
Results: The commercial kits were first compared using serum samples from known
malaria-unexposed individuals (n = 223) and Toxoplasma-infected individuals (n = 191)
to assess specificity and cross-reactivity against non-malaria infections. In addition, 134
samples from ≥10-year-olds collected in a hyperendemic region in the Gambia in the
early 1990s were used to assess sensitivity. Three out of five kits showed high sensitivity
(90–92%), high specificity (98–99%), low cross-reactivity (0–3%) and were considered
user-friendly (Trinity Biotech, newbio and NovaTec). Two of these kits (Trinity Biotech and
NovaTec) were taken forward for epidemiological evaluation and results were compared
to those using the RB-ELISA. Samples from two pre-elimination settings (Praia, Cape
Verde; n = 1,396, and Bataan, the Philippines; n = 1,824) were tested. Serological
results from both the Trinity Biotech kit and the RB-ELISA concurred with recent passively
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detected case counts in both settings. Results from the Trinity Biotech kit reflected a
significant decrease in the number of reported cases in Bataan in the 1990s better
than the RB-ELISA. Results from the NovaTec kit did not reflect transmission patterns in
either setting.
Conclusion: The Trinity Biotech commercial ELISA kit was considered reliable for
epidemiological use and accurately described transmission patterns in two (previously)
malaria endemic settings. The use of this simple and standardized serological tool
may aid national control and elimination programs by confirming that regions are free
from malaria.
Keywords: malaria, elimination, pre-elimination, ELISA, commercial ELISA kits, antibody, immunoglobulin, IgG
INTRODUCTION
A unique property of using antimalarial antibody responses as
a measure of transmission is that when combined with age, they
reflect the infection history of a given population (1–3). Antibody
measures can therefore help to re-create transmission patterns
over time. Evidence for any drop in, or absence of, antibodies
can be interpreted as a decrease in malaria infections, or the
complete cessation of transmission. The cumulative nature of
exposure to malaria and its impact on the underlying antibody
levels would result in smaller sample size needs to describe low
rates of transmission compared to conventional metrics that use
the proportion of infected individuals (4).
Historically, the absence of antibodies in children has been
used as evidence of cessation of transmission in Greece and
Mauritius (5, 6). In these studies, antibody responses to crude
parasite extract were determined using an immunofluorescence
antibody test (IFAT). More recently, studies from Aneityum and
Iran suggested absence of transmission by assessing antibody
responses to individual recombinant antigens (apical membrane
antigen 1; AMA-1, and the 19 kDa fragment of merozoite
surface protein 1; MSP-119) (7, 8) or schizont extract (7) using
an enzyme-linked immunosorbent assay (ELISA). Similar to
the historical studies, children showed no antimalarial antibody
responses, while some adults did have antimalarial antibodies
owing to the persistence of antibodies (and/or memory B cells)
once acquired (9–11). The ELISA platform is considered more
objective than IFAT because antibody reactivity is determined
by measuring optical density (OD) with a spectrophotometer
rather than visual inspection of the strength of fluorescence
using a fluorescence microscope (12). However, at present,
there is no standardized ELISA protocol to measure malaria
antibodies for epidemiological use. In particular, standard
operating procedures, positive controls (i.e., hyperimmune sera)
and negative controls (i.e., unexposed sera), as well as methods of
normalization vary considerably between studies, which makes
direct comparison of results between countries or populations
challenging (4, 13).
There are several commercially available ELISA kits, for which
production and operating procedures are standardized. Until
now, these kits have been used to screen blood donations for
evidence of malaria exposure prior to transfusion (14–20). In
theory, these kits might be redeployed to an epidemiological
context, as illustrated in studies from Ethiopia (21) and Iran
(22). However, experimental evaluation of their use in describing
malaria transmission in endemic settings is lacking. Therefore,
we aimed to compare five of these commercially available
ELISA kits for their applicability and performance in malaria
epidemiology. We firstly assessed applicability by comparing
assay characteristics such as ease-of-use, sensitivity, specificity,
cross-reactivity and the amount of serum needed to test a
sample. Secondly, we tested samples from two pre-elimination
areas from Cape Verde (Praia) and the Philippines (Bataan).
For comparison, a validated research-based ELISA protocol was
performed alongside the commercial kits (1, 3, 23).
METHODS
Study Population
Phase I: Technical Performance of the Commercial
ELISA Kits
Assay performance was based on the proportion of samples
correctly identified as negative using 223 samples from malaria
unexposed UK donors (to assess specificity) as well as 191
samples from Toxoplasma-infected, malaria unexposed UK
donors (to assess cross-reactivity). Malaria naivety was defined
using a questionnaire to exclude malaria risk at the time
of blood donation (14). Toxoplasma was diagnosed with
nine commercially available Toxoplasma IgG and IgM tests
(Supplementary Information) and was considered positive if it
tested positive for any of these tests (J. Newham/A. Kitchen;
unpublished data). To assess assay sensitivity, 134 samples
collected from a hyperendemic region in the Gambia in the early
1990s were used. Sera were stored at −40◦C until transportation
on dry ice to the London School of Hygiene and Tropical
Medicine (LSHTM) and stored at −80◦C. Individuals were
included only if they were 10 years or older by which exposure
to malaria almost certainly would have occurred (24, 25).
Furthermore, costs, the amount of serum needed to test a
sample, and ease-of-use were assessed for all commercial kits
and the research-based ELISA. For ease-of-use, a composite
measure was created based on the number of incubation steps,
total incubation time, need for sample preparation and whether
reagents were ready-to-use.
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FIGURE 1 | Map of survey locations in Bataan, the Philippines (A) and Praia, Cape Verde (C). The square highlighting Cape Verde in (B) is enlarged in (C). The
Philippines (A) and Cape Verde (B,C) are shown in green, study areas are in red and surrounding countries are in gray.
Phase II: Epidemiological Performance of the
Selected Commercial ELISA Kits
Two study sites with contrasting malaria exposure histories and
expected population immunity were selected. Firstly, samples
were collected in Bataan, the Philippines in February 2017
(Figure 1A). In this setting, malaria incidence declined rapidly
in the 1990s (26, 27) and it was declared malaria-free in October
2017 (28). Secondly, samples were collected in historical malaria
hotspots of Praia, Cape Verde (Foton/Tira-Chapéu, Várzea/Taiti
and Achada de Santo António; Figures 1B,C) which has seen
unstable, low transmission since the late 1980s with occasional
outbreaks (29–31). The most recent outbreak started mid-July
2017, with peak cases around the end of August and the end of
October (32, 33). The majority of samples in the current study
were collected before this outbreak (June-July 2017).
A two-stage cluster randomized sampling design was used
with village or a sub-regional administrative unit as primary
sampling unit and household as secondary sampling unit. A
sample size of 2,000 individuals was initially specified for each
setting in order to control the precision of the subsequent
estimates of seroprevalence and seroconversion rates. Under a
cross-sectional survey design, an entomological inoculation rate
of 0.01 and the use of the MSP-119 antigen, this sample size was
expected to generate a 95% confidence interval for seroprevalence
between 4.7% and 6.8% and for the seroconversion rate (SCR;
the annual rate by which seronegative individuals become
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seropositive) between 0.0029 and 0.0043 for African settings,
and 6.1 and 8.5% and 0.0029–0.0043 for non-African settings
(34). This sample size also predicted a power >90% in detecting
absence of malaria exposure for at least 3 years before data
collection (35). For the study in Cape Verde, personnel and
budget constraints led to a reduced sample size. The new
sample size of ∼1,500 individuals was predicted to decrease
estimation precision slightly, with expected 95% confidence
intervals between 4.5 and 7.0% for seroprevalence and ranging
from 0.0028 to 0.0044 for the SCR.
Household members over 6 months old from randomly
selected households were included in the analysis after
consenting participation. A questionnaire was administered
including demographic information and self-reported history
of malaria. Up to 500 µl of whole blood from finger-prick
were collected using microtainers with EDTA (Becton-
Dickinson, Franklin Lakes, New Jersey). Serum was separated at
collaborating institutions in-country and were stored at −20◦C
until shipment on dry ice to the London School of Hygiene and
Tropical Medicine, London, UK. Serum was stored at −20◦C
until sample processing.
Commercial ELISA Kits
Five commercial ELISA kits (Table 1) were used according
to their standard protocols (Table 2): Trinity Biotech, newbio,
DiaPro, Cellabs, and NovaTec. Customer services from both
Trinity Biotech and Bio-Rad confirm that their malaria ELISA
kit is the same. The Trinity Biotech or Bio-Rad kit is also
known in the literature under previous distributers: Newmarket
and Lab21. Optical density (OD) measures were read with a
spectrophotometer (Dynex R© Technologies) at a wavelength of
450 nm with a reference filter of 630 nm and OD measures were
corrected for blank responses for DiaPro, Cellabs, and NovaTec
kits (hereafter: ODcorr) according to the instruction manuals.
Research-Based ELISA
A previously described research-based (RB) ELISA protocol (1, 3,
23) was performedwith the followingmodifications (Tables 1, 2).
To maximize capture of antibody responses in a single assay, a
pool of five P. falciparum antigens was used: apical membrane
antigen 1 (AMA-1) (41), the 19 kDa fragment of merozoite
surface protein 1 (MSP-119) (42), the full-length Dd2 allele of
MSP-2 (MSP-2 Dd2) (43), the full-length CH150/9 allele of
MSP-2 (MSP-2 CH150/9) (44) and glutamate-rich protein R2
(GLURP-R2) (45). The coating concentration for all antigens
was 0.5µg/ml, except for GLURP-R2 which was coated at
0.1µg/ml. To increase throughput andmimic commercial assays,
samples were run in single wells. Samples were tested at a
final concentration of 1:1,000. OD measures were read at a
wavelength of 450 nm, corrected for blank responses (ODcorr)
and normalized using the standard curve as previously described
(23). The standard methodology for the RB ELISA is included in
the Supplementary Information.
Statistical Analyses
All statistical analyses were performed in R version 3.4.1
(46). Antibody responses from infants under the age of 1
year old were removed due to possible presence of maternal
antibodies. For the RB ELISA, a two-Gaussian mixture model
was used to determine seropositivity (1). Seropositivity was
defined at three standard deviations from the mean of the lowest
Gaussian distribution of the mixture model. For commercial
assays, thresholds for seropositivity were calculated according to
manufacturer instruction manuals. For Phase II, results using
seropositivity according to the mixture model approach were
also explored for commercial kits. Histograms of OD values per
assay and thresholds according to each method are provided in
Supplementary Figure 1. Reversible catalytic models were fitted
to the respective seroprevalence data adjusted for age. Themodels
are parameterized by seroconversion and seroreversion rates
(SCR and SRR, respectively), as described elsewhere (2, 3).Where
visual examination suggested a change in transmission, a model
assuming two age-related SCRs was run and fitting tested by
likelihood ratio tests (1, 7).
The following serological metrics were used to show the
presence of low-level recent transmission in Cape Verde and the
absence of recent transmission in the Philippines: seroprevalence
in children aged 1–5 years, SCRs and, where applicable, the
presence of a change point in transmission. In addition, 95%
Pearson-Clopper (exact) confidence intervals (CI) were used
to quantify the uncertainty associated with seroprevalence.
Pearson’s χ2 tests for two-way contingency tables were used
to compare seroprevalence among individuals who reported a
history of malaria and those who did not; Fisher Exact Tests
were used when the counts were below 5. Previous reports on
malaria outbreaks in Cape Verde have identified malaria risk to
be highest in adult men: more than two-thirds of the passively
detected cases between 2007 and 2016 were in men older than
20 years (possibly due to occupational or travel-related risk)
(29, 30). Therefore, seroprevalence in children aged 1 to 5 years
was not used as a metric for absence/presence of malaria in
this setting. Instead, malaria risk in adult men was assessed by
comparing seroconversion models with one force of infection to
those with a change point at age 20 for men (n= 563) and women
(n= 860) separately. A 5% significance level was used throughout
the paper.
RESULTS
Phase I: Technical Performance of the
Commercial ELISA Kits
Sensitivity, testing sera from individuals in a hyperendemic
region in the Gambia in the 1990s as true positives, was high
(90–95%) except for the DiaPro kit (86%); Table 3. Specificity
using samples from either malaria unexposed individuals or
those infected by Toxoplasma was high across most kits
(>96%) except for the Cellabs kit (81 and 84%, respectively).
Receiver operating characteristic (ROC) curves for sensitivity and
specificity estimates are included in Supplementary Figure 2.
Costs per sample were highest for the DiaPro, Cellabs, and
NovaTec kits (>$2 USD compared to <$2 USD for the Trinity
Biotech and newbio kits), while the DiaPro kit needed the
highest volume of serum (150 µl compared to ≤50 µl for
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TABLE 1 | Assay characteristics for five commercial assays according to instruction manuals and the research-based enzyme-linked immunosorbent assay for
antimalarial antibody detection.
Trinity biotech newbio DiaPro Cellabs NovaTec Research-based
Company Trinity Biotech Plc,
Wicklow, Ireland
Newmarket
Biomedical Ltd,
Suffolk, UK
Diagnostic
Bioprobes Srl,
Milan, Italy
Cellabs Pty Ltd.,
Brookvale,
Australia
NovaTec
Immundiagnostica
GmbH, Dietzenbach,
Germany
–
Antigenic targets Four Pf and Pv
recombinant antigens
Recombinant
antigens
Recombinant
proteins
representing
immunodominant
epitopes
A panel of
recombinant
malaria antigens
Pf and Pv
recombinant antigens
Five Pf
recombinant
proteinsa
Detection of
Plasmodium speciesb
Pf, Pv, Pm, Po Pf, Pv, Pm, Po Plasmodium
species
Pf, Pv, Pm, Po Pf, Pv, Pm, Po Pf
Subclasses IgG, IgM, IgA Not reported IgG, IgM, IgA IgG IgG, IgM IgG
Samples/platec 91 91 89 92 91 80
Duration 90min 90min 150min 135min 105min 2.5 days
Plates/run 4 4 4 4 4 40
Specificity:
Specificity from manual
- all species (n)
96% (13,608) 100% (450) >98% (NR) 100% (NR) 98% (NR) –
Specificity from
available literatured (n,
reference standard)
(reference)
100% (8, malaria
naive population) (20)
100%g (50, malaria
naive population) (15)
100%e (17, malaria
naive population) (36)
100%g (23, malaria
naive population) (37)
100% (8, malaria
naive population)
(20)
95% (58, IFAT) (38)
92% (50, malaria
naive population)
(15)
100% (8, malaria
naive population) (20)
92% (245,
microscopy) (39)
80% (96,
microscopy) (40)
–
Sensitivity:
Sensitivity from manual
- all species (n)
NR 98% (528) >95% (NR) 94% (NR) 96% (NR) –
Sensitivity from manual
- Pf only (n)
93% (76) 98% (410) NR NR NR –
Sensitivity from
available literature (n,
reference standard)
(reference)
54%e (56f,
microscopy or history
of malaria) (20)
55%g (11,
microscopy) (15)
53%e (365, history of
malaria) (36)
80%d,g (45,
microscopy and
possible history of
malaria) (37)
64% (56e,
microscopy or
history of malaria)
(20)
71% (145, IFAT)
(38)
91% (11,
microscopy) (15)
55% (56e,
microscopy or history
of malaria) (20)
89% (245,
microscopy) (39)
70% (88,
microscopy) (40)
–
Ig, immunoglobulin, min, minutes, Pf, Plasmodium falciparum; Pv, Plasmodium vivax; Pm, Plasmodium malariae; Po, Plasmodium ovale; n, samples tested; IFAT, immunofluorescence
antibody test; NR, not reported. aAMA-1, MSP1-19, MSP 2 Dd2, MSP2 CH150/9 and GLURP-R2 (for abbreviations and coating concentrations see methods section and
Supplementary Information). bNone of the instruction manuals of commercial kits mention detection of P. knowlesi. cAll assays use 96-well plates and require a certain number of
controls to be run alongside samples. dSome studies estimated specificity according to two methods: (1) using a different malaria diagnostic as the reference standard (e.g., microscopy
or IFAT) or (2) using a malaria naive population (i.e., no travel history to a malaria endemic setting). In these cases, the specificity estimate using a naive population is presented here.
eCustomer services from both Trinity Biotech and Bio-Rad confirm that their kits are the same. fFrom 38 patients (i.e., includes multiple samples from the same participants); authors
reported slight differences in the number of samples tested in each assay. gAlternative names for the Trinity Biotech or Bio-Rad kit can be found in the literature: Newmarket and Lab21.
the other kits) and was considered least user-friendly (Table 3).
Additionally, commercial production of the newbio kit was
discontinued by the manufacturer after the finalization of
Phase I. Based on these considerations, the Trinity Biotech
and NovaTec kits were taken forward for evaluation with
epidemiological samples.
Phase II: Epidemiological Evaluation of the
Selected Commercial ELISA Kits
Bataan, the Philippines
In Bataan, the Philippines, 1,824 out of 2,050 samples collected
were available (Table 4). Seroprevalence in 236 children 1 to
5 years old was 1.7% (n = 4; 95% CI: 0.4–4.3%) for the
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TABLE 2 | Standard operating procedures for five commercial kits and the research-based enzyme-linked immunosorbent assays for antimalarial antibody detection.
Trinity Biotech newbio DiaPro Cellabs NovaTec Research-based
Add sample (Dilution) 50 µl
(neat)
50 µl
(neat)
150 µl
(3:4)
2 µl
(1:100)
10 µl
(1:101)
2 µl
(1:1000)
Incubation, min
(Temperature)
30
(37◦C)
30
(37◦C)
60
(37◦C)
60
(RT)
60
(37◦C)
Overnight
(4◦C)
Wash 1, n 5 5 4-5 4 3 5
Add conjugate 50 µL (prepare) 50 µL #1: 150 µL
(prepare)
#2: 100 µL
100 µL
(prepare)
100 µL 1:15,000 (prepare)
Incubation, min
(Temperature)
30
(37◦C)
30
(37◦C)
#1: 30
#2: 30
(37◦C)
60
(RT)
30
(RT)
180
(RT)
Wash 2, n 5 5 4–5 4 3 5
Add substrate 50 µL 50 µL 200 µL 100 µL
(prepare)
100 µL 100 µL
Incubation
(Temperature)
30
(RT)
30
(RT)
30
(RT)
15
(RT)
15
(RT)
15
(RT)
Add stop 50 µL 50 µL 100 µL 50 µL 100 µL 50 µL
Read plate 450 nm
(reference 630 nm)
450 nm
(reference
630 nm)
450 nm
(reference
630 nm)
450 nm
(blank on air)
450 nm
(reference
630 nm)
450 nm
RT, room temperature; min, minutes.
TABLE 3 | Cost per sample, amount of serum needed to run a sample, ease-of-use, specificity, and cross-reactivity for five commercial kits and the research-based
enzyme-linked immunosorbent assay for antimalarial antibody detection.
Trinity Biotech newbio DiaPro Cellabs NovaTec Research-basedb
Approximate
cost/samplea
$1.59 $1.92 $2.68 $3.04 $2.09 $0.25
Amount of sample 50 µL 50 µL 150 µL 2 µL 10 µL 2 µL
Ease-of-use
Sample preparation
Incubation steps
Incubation time
Ready-to-use reagents
(n/N)
High
No
3
90min
2/3
High
No
3
90min
3/3
Low
Yes
4
150min
3/4
Medium
Yes
3
135min
1/3
High
Yes
3
105min
3/3
–
Yes
3
2x overnight
2/3
Proportion negative for:
Malaria-naive (n = 223) 99%
(97–100%)
99%
(97–100%)
98%
(95–99%)
81%
(75–86%)
98%
(95–100%)
–
Toxoplasma-exposed
and malaria-naive
(n = 191)
100%
(98–100%)
99%
(96–100%)
100%
(98–100%)
84%
(78–89%)
98%
(95–99%)
–
Proportion positive for:
Malaria-exposedc
(n = 134)
92%
(88–95%)
91%
(86–94%)
86%
(81–91)
95%
(91–97%)
90%
(85–93%)
–
aCosts per sample are based on running a 96-well plate of samples except for wells allocated for necessary controls (see Table 1); it does not include technician time. Commercial
assays were bought in bulk (i.e. 25 plates per brand) in January 2016 for Phase I and March 2017 for Phase II. Costs shown are based on the most recent prices for Trinity Biotech and
NovaTec. bEvaluation of assay performance (Phase I) focused on the commercial assays, however, where available, information for the research-based assay is included for reference.
cSera were collected in a hyperendemic region in the Gambia in the early 1990s and individuals were only included if they were 10 years or older by when exposure to malaria almost
certainly would have occurred (24, 25).
Trinity Biotech kit; 4.7% (n = 11; 2.3–8.2%) for the NovaTec
kit; and 1.7% (n = 4; 0.4–4.3%) for the RB-ELISA. The best
fit seroconversion curve for the Trinity Biotech kit showed
a change point at 22.0 years (95% CI: 20.0–23.5, p < 0.001;
Figure 2b), which coincides with the marked decrease in locally
reported cases ∼22 years previously (Figure 2a). The RB-ELISA
also showed a change in the seroconversion curve (p < 0.001),
though estimated at 41.5 years ago with a wider 95% confidence
interval (28.5–45.5). The SCR estimates ranged from 0.001
annual seroconversion events per person (95% CI: 0.001–0.002)
for the Trinity Biotech kit; 0.003 (0.002–0.004) for the RB-ELISA;
and 0.013 (0.010–0.016) for the NovaTec kit. For all assays,
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TABLE 4 | General characteristics of the study population in Bataan, the
Philippines and Praia, Cape Verde.
Bataan,
the Philippines
Praia,
Cape Verde
Number of samples collected 2,050 1,432
- Number of samples analyzed in assays
- No age data available or <1-year-old
- Not enough serum available for all tests
Lived outside of main study area
1,824
11
179
36
1,396
33
11
N/A
Age group, % (n)
- 1 to 5
- 6 to 15
- >15
12.9% (236)
26.0% (475)
61.0% (1,113)
8.3% (116)
22.9% (319)
68.8% (961)
Self-reported history of malaria, % (n/N)
Youngest participant with self-reported
history of malaria
4.8%
(87/1,812)
10 years old
1.8%
(25/1,394)
16 years old
seroprevalence in those with self-reported history of malaria
(n = 87) was higher compared to those without (p < 0.001) but
this difference was greatest for the Trinity Biotech kit (Figure 2c).
Continuous OD measurements before and after the detected
change point showed marked differentiation for the Trinity
Biotech kit but less so for the NovaTec kit and the RB-ELISA
(Supplementary Figure 3). Seropositivity in those younger than
22 years (i.e., those born since the marked decrease in reported
cases in 1995) was low for the Trinity Biotech kit (1.3%, 12/902;
0.7–2.3%) and the RB-ELISA (2.4%, 22/902; 1.5–3.7%), compared
to the NovaTec kit (8.0%, 72/902; 6.3–10.0%). Antibody levels
in these seropositives were relatively weak (i.e., OD<1) for the
Trinity Biotech kit, except for one child (OD: 2.523; age: 12). For
the RB-ELISA, only three had an ODcorr >1 (ages: 9, 6 and 3)
and for the NovaTec kit this was twelve (age range: 1–18). Very
few were seropositive in multiple assays (n = 3, ages 3, 9 and 16;
Figure 3) and none had an OD/ODcorr >1 in multiple assays.
Praia, Cape Verde
In Cape Verde, 1,396 out of 1,432 samples collected were
available for analyses (Table 4). For the Trinity Biotech kit and
the RB-ELISA, (recent) SCRs were low (Figure 2e), consistent
with historically low case counts (Figure 2d), with 0.003 annual
seroconversion events per person for each assay. The SCR
for the NovaTec kit was high (0.128 annual seroconversion
events per person, 0.096–0.172), but when using the mixture
model approach to define seropositivity instead of the kit-
based threshold, the SCR was lower (0.032, 0.022–0.048;
Supplementary Figure 4). Few participants reported a history of
malaria (n = 25; Table 4). Seroprevalence was higher in those
who did vs. those who did not for both the Trinity Biotech
kit (odds ratio, OR, 8.91, 95% CI: 3.68–20.47; p < 0.001) and
the RB-ELISA (OR 4.82, 1.37–13.22; p = 0.005). This difference
was not statistically significant for the NovaTec kit (OR 1.23,
0.56–2.79; p = 0.612; Figure 2f). Both the RB-ELISA and the
Trinity Biotech kit showed evidence of an increased SCR in
adult men (i.e., p = 0.060 and p = 0.026 comparing models
with and without a change point at 20 years for men only;
Supplementary Table 1). For women as well as men and women
combined, this was not seen. Using mixture models to define the
seropositivity threshold, there was some evidence for a higher
SCR in those aged<2–3 years using the Trinity Biotech kit (0.020
vs. 0.003; p = 0.009) and the RB-ELISA (0.007 vs. 0.001; p =
0.090), Supplementary Table 1. However, in both cases, this was
based on only 1 seropositive infant and ODs were low (Trinity
Biotech kit: 1/26 infants aged 1-2, OD 0.071; RB-ELISA: 1/54
infants aged 1-3, ODcorr 0.372). For the NovaTec kit, the SCR
was zero for those aged 3 or less but with a wide 95% CI (2.0–15.0
years; Supplementary Table 1).
DISCUSSION
There is historical evidence that demonstrating the absence
of specific antibody responses can contribute to verifying
areas or populations as malaria-free (5, 6), but there is no
standardized approach available. Commercially available ELISA
kits undergo rigid standardization processes and have been
applied to screen blood products prior to donation to minimize
risks of transfusion-transmitted malaria (14–20). Here, we
compared five commercial kits alongside a research-based (RB)
ELISA for their technical (Phase I) and epidemiological (Phase
II) performance in characterization of malaria transmission at
low endemicity and pre-elimination. In technical performance
assessments, three kits were discounted from further analysis
due to poor sensitivity (DiaPro), poor specificity (Cellabs),
high cross-reactivity to Toxoplasma gondii (Cellabs), low ease-
of-use (DiaPro), high required blood volume (DiaPro) or
production being discontinued (newbio). Further evaluation of
kits in epidemiological characterization with samples from the
Philippines and Cape Verde found that the Trinity Biotech kit
described historical and recent malaria transmission patterns
most accurately.
Firstly, we used serum samples from a hyperendemic region
and those from malaria naive populations to assess sensitivity
and specificity. Specificity estimates for the kits reported here and
from previous studies were largely similar to those reported in
instruction manuals (Tables 1, 3). Specificity was slightly lower
where previous studies used samples from endemic settings and
microscopy was the reference standard, as opposed to using
samples from a malaria naive population. Sensitivity estimates
from the available literature were considerably lower than those
presented by us and instruction manuals. This may be due to
the fact that previous studies have used microscopy or IFAT
positivity as the reference standard and/or samples from non-
endemic settings (i.e., returning travelers with a clinical history
of malaria), whereas we used sera collected in a hyperendemic
region. Overall, this highlights the need for a reliable reference
standard (i.e., confirmed recent infection) to generate estimates
for these and other serological assays.
Our rationale for extending technical performance evaluation
with ease-of-use and costs was that whilst ELISA kits used
for blood screening may have undergone some level of
standardization, their intended use case scenario is different
from epidemiological screening. Kits are typically designed to
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FIGURE 2 | Reported malaria cases (a,b), seroconversion curves (c,d) and seroprevalence by self-reported history of malaria (e,f) using antibody responses recorded
by commercial and the research-based (RB) enzyme-linked immunosorbent assays. In (a,b) counts of reported malaria cases at local health facilities are shown over
time; in Bataan, data was available for 0 to 12 years prior to data collection (i.e., 2017 – 2005) (28) and 21–35 years prior to data collection (i.e., 1996 – 1982) (26). In
Praia, data was available from 1 to 21 years prior to data collection (i.e., 2016 – 1996) (30) and 22 to 31 years prior to data collection (i.e., 1995 – 1986) (29). In (c,d)
seroconversion curves of age-specific seroprevalence are shown; solid lines represent the fit of the reversible catalytic model (2), while dashed lines represent 95%
confidence intervals (CIs). Seroconversion rate and change point estimates with 95% CIs are shown on plots. In (e,f) seroprevalence estimates and 95% CIs are
shown by self-reported history of malaria. Results for commercial kits using a two-Gaussian mixture model for seropositivity thresholds are shown in
Supplementary Figure 4.
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test batches of dozens to hundreds of samples, whereas a study
to verify the absence of malaria transmission may include
hundreds (7) or even thousands of participants (47). Ease-of-
use, cost and scalability to large epidemiological studies are thus
important considerations. Whilst rudimentary, our screen found
that some assays were significantly more protracted to complete
than others and used higher blood volumes than those that
might be collected in epidemiological surveys. Blood collection
FIGURE 3 | Venn diagram showing the intersection of seropositivity recorded
by commercial and the research-based (RB) enzyme-linked immunosorbent
assays in those born since the decline in passively detected malaria cases in
Bataan, the Philippines. Seropositivity is shown for those younger than 22
years corresponding to the marked decline in passively detected cases in
1995, see Figure 2a. Ages are shown on the plot for individuals who were
seropositive in multiple assays.
in surveys is typically done via fingerprick resulting in 50–
500 µl sample volumes depending on age and/or compliance
and may be stored as separated liquid plasma/serum or dried
onto filter papers (Dried Blood Spot, DBS). Excision and
elution of DBSs is time consuming but can outweigh the need
for cold chain which has significant practical and logistical
advantages in field surveys (23). It was for this latter reason
that we included a research-based (RB) ELISA which has been
developed, and extensively tested, for use with DBS samples
(1, 3, 23).
Although this was not an exhaustive assessment of all
currently available commercial ELISA kits for antimalarial
antibody detection, one of the five kits showed significant
promise in correlating with described transmission patterns in
two endemic settings. In Bataan, The Philippines, seroconversion
curve profiles generated from the Trinity Biotech kit
corresponded with a decrease in passively detected malaria cases
in 1995 (26). Seroprevalence in those born since this decrease
in transmission was low (1.3%). Whether these represent
false-positive results or true responses following asymptomatic,
low-density infections or infections acquired outside the study
area, is unknown. However, ODs were relatively low and very
few were positive in multiple assays which suggests that these are
false-positive observations. Additionally, the current estimate of
seroconversion was low in Bataan, 0.001 annual seroconversion
events per person, which is lower than that recorded in Sri
Lanka during pre-elimination using a RB-ELISA protocol (48).
Bataan was declared malaria-free shortly after samples were
collected for this study (28). Although the RB-ELISA detected
a change point in transmission in the site in the Philippines,
this preceded the drop in reported cases to local health facilities
(including the lower estimate from the 95% confidence interval
for the change point). This is perhaps a result of decreased
sensitivity due to the higher sample dilution (1:1000 for the
RB-ELISA vs. neat for the Trinity Biotech kit) or a (previous)
behavior-related risk of exposure to malaria. Lastly, the decreased
sensitivity could have been caused by the RB-ELISA detecting
P. falciparum alone, while the commercial kits additionally
detect non-falciparum species (except for P. knowlesi).
BOX 1 | Future work: Technological re nements of the antimalarial antibody detection assays and programmatic questions that need to be addressed for their
use in con rmation of malaria elimination.
Technological refinements
- Broaden assessments of sensitivity and specificity from non-malaria infections
- Optimize assays for use with dried blood spots
- Evaluate options for scenario-specific assays by selecting antibodies with known exposure profiles (i.e., recent vs. any) or specific Ig class responses
- Confirm suitability for non-Plasmodium falciparum species
- Evaluate best methodology to determine seropositivity at (very) low transmission
Programmatic questions
- Revisit costs per sample (aiming for <1 USD/sample)
- Establish limits of non-specific reaction (i.e., false-positivity rate)
- Establish sampling frames for specific epidemiological scenarios and disease transmission patterns; i.e., determine who and where to sample to confirm absence
of malaria transmission (with consideration of age- and/or behavior-related risk of malaria)
- Improve understanding of relationship between seroprevalence, SCR and annual parasite incidence (API)/entomological inoculation rate (EIR) at (very)
low transmission
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Historically, P. vivax was also present in Bataan like much of
the Philippines.
For Cape Verde, the low levels of transmission over
the past decades were correctly identified as shown by
the low, constant SCR recorded by the Trinity Biotech
kit (i.e., 0.003 annual seroconversion events per person).
The Trinity Biotech kit also identified a higher exposure
to malaria in adult men (i.e., >20 years old compared to
those younger than 20 years old) as previously described in
epidemiological studies in Cape Verde (29, 30). Seroconversion
curves generated from results from the RB-ELISA were
similar to those for the Trinity Biotech kit in Cape Verde.
Results from the NovaTec kit did not reflect malaria
transmission patterns in either setting and therefore it
probably has limited utility for epidemiological characterization
of transmission.
The dynamic range of OD values recorded in endemic
populations was greatest for the Trinity Biotech kit and despite
the use of neat serum, little to no background responses were seen
(Supplementary Figure 3), thus blocking of non-specific binding
to malaria antigens seems extremely efficient. Another advantage
of commercial kits over the RB-ELISA is that both kits (Trinity
Biotech and NovaTec) report detection of IgM and IgG, while
the RB-ELISA detects only total IgG, and IgM may be more
informative in representing a recent infection. An optimal assay
would be refined to use DBS whilst maintaining high accuracy
together with reducing costs (i.e., currently >$1.50/sample for
commercial kits vs. approximately $0.25/sample for the RB-
ELISA, excluding technician time). An overview of these and
other outstanding technological refinements for assays as well
as programmatic questions that need to be addressed are shown
in Box 1.
CONCLUSION
The Trinity Biotech commercial ELISA kit was considered
most applicable for large-scale use in epidemiological surveys
and accurately described malaria transmission in two pre-
elimination settings. All the commercial ELISA kits studied
reported the detection of four human malaria species: P.
falciparum, P. vivax, P. malariae, and P. ovale, but the accuracy
of these assays in detecting exposure to P. knowlesi is unknown.
The performance of the kits using DBS samples remains to
be evaluated. Future work should focus on these technological
refinements as well as outstanding programmatic questions
relevant to the use of serological tools for certification of malaria-
free populations.
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